HY
HYI
Western Asset High Yield Opportunity Fund Inc.
$10.62
0.00%
No data for this timeframe.
Vol
Inst. Holders14 funds
Inst. Value$19.0M
Inst. Activity2 buys / 0 sells
SEC Reports1
Recent Activity
Apr 2, 2026
SEC
Analysis based on filing metadata only — document content was unavailable. The filing is an EFFECT notice indicating tha
EFFECT — Impact 3/10
Inst.
WOLVERINE ASSET MANAGEMENT LLC — DOUBLED
201,953 shares ($2.3M)
Inst.
BANK OF AMERICA CORP — ADD
31,976 shares ($356.9K)
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RAYMOND JAMES FINANCIAL INC | $5.6M | — |
| GUGGENHEIM CAPITAL LLC | $4.3M | — |
| WOLVERINE ASSET MANAGEMENT LLC | $2.5M | DOUBLED |
| Rockefeller Capital Management L.P. | $1.9M | ADD |
| MORGAN STANLEY | $1.2M | TRIM |
14 institutional holders with $19.0M total value (1,795,104 shares) as of 2026-Q1. Top holders: RAYMOND, GUGGENHEIM, WOLVERINE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RAYMOND JAMES FINANCIAL INC | 526,763 | $5.6M | 29.6% | — |
| 2 | GUGGENHEIM CAPITAL LLC | 399,078 | $4.3M | 22.4% | — |
| 3 | WOLVERINE ASSET MANAGEMENT LLC | 236,872 | $2.5M | 13.3% | DOUBLED +760.0% |
| 4 | Rockefeller Capital Management L.P. | 173,763 | $1.9M | 9.8% | ADD +96.1% |
| 5 | MORGAN STANLEY | 116,595 | $1.2M | 6.5% | TRIM -26.0% |
| 6 | WELLS FARGO & COMPANY/MN | 92,463 | $987.5K | 5.2% | TRIM -59.7% |
| 7 | CITADEL ADVISORS LLC | 74,540 | $796.1K | 4.2% | — |
| 8 | Invesco Ltd. | 56,886 | $607.5K | 3.2% | ADD +57.1% |
| 9 | JONES FINANCIAL COMPANIES LLLP | 43,329 | $454.1K | 2.4% | — |
| 10 | BANK OF AMERICA CORP /DE/ | 33,611 | $359.0K | 1.9% | ADD +46.9% |
| 11 | NOMURA HOLDINGS INC | 14,445 | $154.3K | 0.8% | — |
| 12 | FIFTH THIRD BANCORP | 7,232 | $77.2K | 0.4% | — |
| 13 | ROYAL BANK OF CANADA | 6,073 | $65.0K | 0.3% | ADD +25.6% |
| 14 | HRT FINANCIAL LP | 13,454 | $143.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | 23,483 | 201,953 | +760.0% | $2.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 21,764 | 31,976 | +46.9% | $356.9K | 2025-Q4 |
| Rockefeller Capital Management L.P. | ADD | 82,663 | 162,119 | +96.1% | $1.9M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 295,781 | 119,159 | -59.7% | $1.4M | 2025-Q3 |
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | 611 | 23,483 | +3743.4% | $275.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 39,569 | 21,764 | -45.0% | $254.9K | 2025-Q3 |
| UBS Group AG | ADD | 28,121 | 38,187 | +35.8% | $452.1K | 2025-Q1 |
| STIFEL FINANCIAL CORP | TRIM | 40,850 | 16,750 | -59.0% | $198.3K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 224,297 | 165,971 | -26.0% | $2.0M | 2024-Q4 |
| Invesco Ltd. | ADD | 44,340 | 69,646 | +57.1% | $823.2K | 2024-Q4 |
| Concurrent Investment Advisors, LLC | ADD | 12,047 | 15,138 | +25.7% | $178.9K | 2024-Q4 |
| ROYAL BANK OF CANADA | ADD | 3,898 | 4,894 | +25.6% | $61.0K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.